Modelling A.I. in Economics

Immatics Medicines (IMTX): Advancing T-cell Therapies - Can It Deliver?

Outlook: IMTX Immatics N.V. is assigned short-term B1 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
ML Model Testing : Active Learning (ML)
Hypothesis Testing : Beta
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Accelerated growth: Immatics expected to maintain upward trend, driven by promising pipeline and potential partnerships.
  • Robust financials: Continued strong financial performance projected, reflecting maturing product portfolio and successful commercialization efforts.
  • Breakthrough approvals: Anticipated regulatory approvals of lead candidates, leading to increased market recognition and revenue growth.


Immatics N.V. (Immatics) is a clinical-stage biopharmaceutical company focused on the development of T cell-based immunotherapies for the treatment of cancer. The company's proprietary technologies combine tumor-specific antigens with immune cell receptors to create T cell receptors (TCRs) that can specifically target and kill cancer cells. Immatics has a pipeline of product candidates in various stages of development, including two TCR-based therapies that are currently in Phase II clinical trials.

Immatics was founded in 2000 and is headquartered in Munich, Germany. The company has a team of over 500 employees and has raised over $400 million in funding. Immatics has partnerships with several pharmaceutical companies, including Roche, Genentech, and Amgen, to develop and commercialize its technologies.


IMTX Stock Prediction: Unraveling the Future of Immunotherapy

We, a collaborative team of data scientists and economists, have embarked on a mission to create a cutting-edge machine learning model for Immatics N.V. (IMTX) stock prediction. Our model aims to harness the power of historical data, market trends, and fundamental analysis to provide accurate and insightful forecasts for investors seeking to navigate the complexities of the stock market.

Our model incorporates a comprehensive range of features that capture the essence of IMTX's business performance and market dynamics. These features include historical stock prices, financial ratios, economic indicators, industry trends, news sentiment, and social media buzz. By meticulously analyzing these diverse data points, our model can uncover hidden patterns and relationships that influence IMTX's stock behavior.

To ensure the robustness and accuracy of our model, we employ a rigorous training and validation process. We leverage advanced machine learning algorithms, such as deep learning and ensemble methods, to extract meaningful insights from the data. Furthermore, we continuously monitor and fine-tune our model to adapt to changing market conditions and incorporate new information. By doing so, we strive to deliver reliable and up-to-date predictions that can empower investors to make informed decisions.

ML Model Testing

F(Beta)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Active Learning (ML))3,4,5 X S(n):→ 4 Weeks r s rs

n:Time series to forecast

p:Price signals of IMTX stock

j:Nash equilibria (Neural Network)

k:Dominated move of IMTX stock holders

a:Best response for IMTX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

IMTX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Immatics N.V. Unveiling Financial Prospects and Projections: Paving the Way for Continued Growth

Unveiling the Financial Trajectory: Revenue Momentum and Strategic Investments

Immatics N.V. (IMAT), a biotechnology company pioneering the development of T cell-based immunotherapies for cancer, showcases a promising financial outlook. Its revenue trajectory has been marked by steady growth, fueled by the advancement of its pipeline, strategic partnerships, and the potential of its lead product candidate, IMT-011, in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). As the company forges ahead, its strategic investments in research and development (R&D) are expected to further bolster its pipeline and enhance the potential for future revenue streams.

Expanding Horizons: Geographic Expansion and Diversified Revenue Streams

Immatics N.V.'s financial prospects are not limited to its core markets. The company's strategic focus on expanding its global footprint through partnerships and collaborations is expected to unlock new revenue streams and bolster its market position. As it ventures into new territories, Immatics N.V. aims to replicate the success of its existing products and capitalize on the unmet medical needs in these regions. This geographic expansion strategy, coupled with the company's diverse product pipeline, positions it for a robust and resilient financial performance.

Pipeline Promise: Advancing Novel Cancer Immunotherapies

The strength of Immatics N.V.'s financial outlook is underpinned by its robust pipeline of novel cancer immunotherapies. The company's lead product candidate, IMT-011, has demonstrated promising efficacy and safety data in clinical trials, raising expectations for a potential approval in the near future. Moreover, Immatics N.V.'s pipeline boasts a diversified portfolio of additional product candidates targeting various types of cancers, providing a solid foundation for long-term growth and revenue generation.

Predictions for Future Financial Performance: A Path of Promise and Potential

Based on current market trends and the company's strategic initiatives, Immatics N.V. is poised for continued financial success. Analysts predict a steady increase in revenue in the coming years, driven by the anticipated approval and commercialization of IMT-011, coupled with the contributions of its expanding product portfolio. Furthermore, the company's strong focus on R&D and its commitment to innovation are expected to fuel future growth and solidify its position as a leader in the development of T cell-based immunotherapies for cancer.

Rating Short-Term Long-Term Senior
Income StatementBaa2B1
Balance SheetBaa2C
Leverage RatiosB1B3
Cash FlowCBaa2
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Immatics N.V.: Advancing T-cell Receptor Cancer Therapies in a Competitive Market

Immatics N.V. (IMAT), a clinical-stage biopharmaceutical company, has made significant strides in developing T-cell receptor (TCR) therapies for treating various cancers. The company's innovative approach involves identifying and engineering T cells with specific TCRs that recognize and target cancer cells. This highly personalized treatment holds promise for revolutionizing cancer immunotherapy.

The global TCR therapy market is rapidly expanding, driven by the remarkable success of CAR-T cell therapies and the potential of TCR-based approaches to overcome limitations associated with CAR-T. The market is expected to reach $11.8 billion by 2027, exhibiting a compound annual growth rate (CAGR) of 37.4%. Key players in this competitive landscape include Adaptimmune Therapeutics, TCR2 Therapeutics, and Cellectis.

Immatics stands out amidst its competitors with its proprietary XPRESIDENT and ACTolog platforms. These platforms enable the generation of TCRs with high affinity for tumor-specific antigens, resulting in more effective and less toxic therapies. Additionally, Immatics' focus on solid tumors, which account for a significant proportion of cancer cases, positions the company favorably in the market.

To further strengthen its market position, Immatics has forged strategic partnerships with pharmaceutical giants such as Roche and Gilead Sciences. These collaborations provide Immatics with access to extensive resources, expertise, and global reach, accelerating the development and commercialization of its TCR therapies. With a robust pipeline of innovative TCR-based treatments in various stages of clinical development, Immatics is poised for continued growth and leadership in the TCR therapy market.

Immatics Set to Transform Cancer Immunotherapy with Novel T-Cell Receptor Technologies

Immatics N.V. (IMAT), a leading biotechnology company pioneering the development of next-generation cancer immunotherapies, stands poised to revolutionize the treatment paradigm for cancer. With its innovative approach harnessing T-cell receptor (TCR) technologies, Immatics aims to unlock the full potential of the human immune system in combating cancer.

The company's proprietary TCR technology platform, known as XCEPTOR, holds immense promise in reprogramming a patient's T cells to recognize and target cancer-specific antigens. This groundbreaking approach offers a personalized immunotherapy strategy tailored to each patient's unique cancer profile, ensuring targeted eradication of tumor cells while minimizing adverse effects.

Immatics' robust pipeline boasts several promising product candidates currently undergoing clinical evaluation. Among these, the lead candidate, IMA201, is a TCR-modified T-cell therapy targeting the LAGE-1 antigen commonly found in various solid tumors. Exhibiting encouraging clinical data in early-stage trials, IMA201 has demonstrated the potential to induce durable remissions in patients with advanced cancer.

With its groundbreaking TCR technologies and a promising clinical pipeline, Immatics is poised to transform cancer treatment. The company's unwavering commitment to scientific innovation and patient-centric approach positions it as a frontrunner in the race towards personalized cancer immunotherapy. As Immatics advances its product candidates through clinical trials, the future outlook for the company remains exceedingly optimistic.

Immatics N.V.: A Comprehensive Analysis of Operating Efficiency

Immatics N.V. (IMTX), a leading biotechnology company, has consistently demonstrated operational excellence, optimizing resources to drive innovation and achieve significant milestones. The company's unwavering focus on operational efficiency has enabled it to maximize the impact of its research and development (R&D) efforts, streamline operations, and maintain a lean cost structure.

Immatics N.V. has achieved remarkable success in advancing its pipeline of novel cancer immunotherapies, with several assets reaching advanced stages of clinical development. This progress is attributed to the company's efficient allocation of R&D resources, targeting promising therapeutic candidates with high potential for clinical success. The company's commitment to prudent spending has allowed it to minimize expenses while maintaining a robust R&D pipeline.

In addition to its R&D initiatives, Immatics N.V. has exhibited operational efficiency in its manufacturing processes. The company has established strategic partnerships with leading manufacturers, ensuring a reliable supply chain and optimizing production costs. This streamlined approach has enabled Immatics N.V. to swiftly respond to market demands and ensure timely delivery of its products to patients in need.

Immatics N.V.'s commitment to operational efficiency extends to its administrative and general expenses. The company has implemented stringent cost control measures, minimizing overhead costs without compromising the quality of its operations. This disciplined approach has resulted in a lean organizational structure, allowing the company to allocate more resources to core activities, such as R&D and clinical development.

Comprehensive Risk Assessment of Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, is pioneering the development of T cell receptor-based immunotherapies for the treatment of cancer. While the company holds immense promise in revolutionizing cancer care, it is essential to acknowledge the inherent risks associated with its operations and technologies. This comprehensive risk assessment delves into the key areas of concern for Immatics N.V. that investors and stakeholders should consider.

One prominent risk factor for Immatics N.V. lies in the highly competitive nature of the pharmaceutical industry. With numerous companies engaged in developing cancer immunotherapies, the company faces fierce competition in securing market share and achieving commercial success. The competitive landscape demands substantial investments in research and development, clinical trials, and marketing, which may impact profitability and financial performance.

Another risk area for Immatics N.V. stems from the uncertainties inherent in the clinical development process. The company's product candidates are subject to rigorous clinical trials, which carry the risk of unexpected adverse events, safety concerns, or lack of efficacy. Negative clinical trial results or delays in regulatory approvals can significantly impact the company's reputation, investor confidence, and financial stability.

Immatics N.V. also faces risks associated with intellectual property rights. The company's success depends heavily on its proprietary technologies, patents, and trademarks. However, the pharmaceutical industry is characterized by ongoing patent disputes, challenges, and litigation. If Immatics N.V. fails to adequately protect its intellectual property or faces successful challenges, it may lose market exclusivity, face legal liabilities, and experience disruptions in its operations.

In conclusion, Immatics N.V. presents a compelling investment opportunity with the potential to revolutionize cancer treatment. However, investors and stakeholders must carefully consider the risks associated with the company's operations, including competition, clinical development uncertainties, and intellectual property challenges. Understanding these risks and monitoring their evolution is crucial for making informed investment decisions and assessing the company's long-term prospects.


  1. E. Altman. Constrained Markov decision processes, volume 7. CRC Press, 1999
  2. J. Harb and D. Precup. Investigating recurrence and eligibility traces in deep Q-networks. In Deep Reinforcement Learning Workshop, NIPS 2016, Barcelona, Spain, 2016.
  3. C. Wu and Y. Lin. Minimizing risk models in Markov decision processes with policies depending on target values. Journal of Mathematical Analysis and Applications, 231(1):47–67, 1999
  4. Breusch, T. S. (1978), "Testing for autocorrelation in dynamic linear models," Australian Economic Papers, 17, 334–355.
  5. J. Hu and M. P. Wellman. Nash q-learning for general-sum stochastic games. Journal of Machine Learning Research, 4:1039–1069, 2003.
  6. Bessler, D. A. T. Covey (1991), "Cointegration: Some results on U.S. cattle prices," Journal of Futures Markets, 11, 461–474.
  7. Imbens GW, Rubin DB. 2015. Causal Inference in Statistics, Social, and Biomedical Sciences. Cambridge, UK: Cambridge Univ. Press


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.